Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.

175.20 8.97 −4.87%
Market cap
$11.7B
P/E
234×
Fwd P/E
112×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

0.08% 2.40% 2.51% 1.99%
Piotroski F-Score
6 6 7 7
ROA
0.06% 1.69% 1.78% 1.42%
ROIC
0.03% 1.83% 2.16% 2.18%
Return on Tangible Assets
0.15% 4.12% 4.25% 3.36%
Average Days of Receivables
76.81 78.41 72.47 73.32
Free Cash Flow per Share
1.87 1.63 1.86 1.96
Free Cash Flow
105.23 91.93 104.66 110.35
Other line items

Show all line items

Columns are period end dates